Group One Trading
ABOS icon

Group One Trading’s Acumen Pharmaceuticals ABOS Stock Holding History

Group One Trading’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13K Buy
+5,500
New +$14K ﹤0.01% 6218
2025
Q2 		– Sell
-3,200
Closed -$3.52K – 7848
2025
Q1 		$3.52K Sell
3,200
-35,100
-92% -$50.1K ﹤0.01% 6788
2024
Q4 		$65.9K Sell
38,300
-93,200
-71% -$224K ﹤0.01% 4850
2024
Q3 		$326K Buy
131,500
+5,700
+5% +$15.5K ﹤0.01% 3189
2024
Q2 		$304K Buy
125,800
+93,800
+293% +$299K ﹤0.01% 3027
2024
Q1 		$130K Buy
32,000
+5,500
+21% +$20.7K ﹤0.01% 3914
2023
Q4 		$102K Buy
26,500
+13,800
+109% +$41K ﹤0.01% 4454
2023
Q3 		$52.7K Sell
12,700
-7,300
-37% -$45.1K ﹤0.01% 5054
2023
Q2 		$96.2K Hold
20,000
– – ﹤0.01% 4668
2023
Q1 		$81.2K Sell
20,000
-1,000
-5% -$5.22K ﹤0.01% 4478
2022
Q4 		$113K Sell
21,000
-14,000
-40% -$94.1K ﹤0.01% 4325
2022
Q3 		$351K Buy
+35,000
New +$201K ﹤0.01% 3571

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Group One Trading's ABOS Position: Q1 2026 in Review

Group One Trading reduced its Acumen Pharmaceuticals (ABOS) stake by 69% in Q1 2026, selling an estimated $8.36K and leaving 1,475 shares worth $3.48K. The position accounts for ﹤0.01% of the portfolio, ranked #6863.

Group One Trading first reported a position in ABOS in Q3 2022 and has held it in 14 quarters since. The position peaked at $304K in Q3 2024. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Group One Trading held 1,475 shares of Acumen Pharmaceuticals worth $3.48K as of Q1 2026.
  • Group One Trading sold 3,277 Acumen Pharmaceuticals shares in Q1 2026, an estimated $8.36K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6863 holding.
  • Group One Trading first reported a position in Acumen Pharmaceuticals in Q3 2022 and has held it in 14 quarters since.
  • Group One Trading's Acumen Pharmaceuticals position peaked at $304K in Q3 2024.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.